Compare Amphastar Pharmaceuticals Inc (AMPH) vs Tyson Foods, Inc. (TSN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Tyson Foods, Inc. — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Tyson Foods, Inc. trades at $57.91 (market cap $20.36B). The key difference: Tyson Foods, Inc. is far larger — about 24.6× Amphastar Pharmaceuticals Inc's market cap, and Tyson Foods, Inc. pays a 3.53% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | TSN | |
|---|---|---|
Market Cap | $826.08M | $20.36B |
Sector | Health | Consumer Staples |
52-Week High | $30.81 | $68.75 |
52-Week Low | $16.87 | $50.72 |
Enterprise Value | $1.22B | $27.95B |
Dividend Yield | — | 3.53% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Tyson Foods (TSN) trades at $57.83, showing modest daily gains. The stock presents mixed signals with a bearish technical outlook but strong analyst support (50% buy ratings) and a consensus price target of $69.75. Recent earnings have beaten expectations in two of the last three quarters, while fundamentals show stable revenue near $54.4 billion but thin net margins of 0.81%. The company maintains dividend payments and is focusing on prepared foods growth.
The investment case balances value metrics like low P/S of 0.37 against profitability challenges. Upside potential exists if margin improvements materialize, but risks include volatile input costs and competitive pressures. The stock appears undervalued relative to analyst targets, suggesting cautious optimism for patient investors despite near-term headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Tyson Foods, Inc.
Tyson Foods is the largest U.S. producer of processed chicken and beef. It's also a large producer of processed pork and protein-based products under the brands Jimmy Dean, Hillshire Farm, Ball Park, Sara Lee, Aidells, State Fair, and Raised & Rooted, to name a few. Tyson sells 81% of its products through various U.S. channels, including retailers (47% in fiscal 2021), food service (32%), and other packaged food and industrial companies (10%). In addition, 11% of the company's revenue comes from exports to Canada, Mexico, Brazil, Europe, China, and Japan.
Read more on TSN →
